Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression

Affiliations

• ¹ Peter MacCallum Cancer Centre, Royal Melbourne Hospital and University of Melbourne, Victoria, NSW, Australia.
• ² Kings College Hospital, London, UK.
• ³ Cancer Research UK Centre, University of Southampton, Southampton, UK.
• ⁴ Velindre Cancer Centre, Cardiff, UK.
• ⁵ Austin Hospital, Melbourne, Victoria, NSW, Australia.
• ⁶ Nottingham University Hospitals NHS Trust, Nottingham, UK.
• ⁷ HELIOS-Klinikum Erfurt, Germany.
• ⁸ BAG Freiberg-Richter, Jacobasch, Illmer and Wolf, Dresden, Germany.
• ⁹ Section of Hematology and Coagulation, Department of Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden.
• ¹⁰ Eberhard-Karls-University Tübingen, Tübingen, Germany.
• ¹¹ Roche Pharma AG, Grenzach-Wyhlen, Germany.
• ¹² F. Hoffmann-La Roche Ltd., Basel, Switzerland.
• ¹³ Department of Medicine III, Ludwig-Maximilians-University, München, Germany.